Evidence map›Paper›PMID 33450992›Full record

ArticleMolecules (Basel, Switzerland)2021

Design, Synthesis and Biological Evaluation of Arylpyridin-2-yl Guanidine Derivatives and Cyclic Mimetics as Novel MSK1 Inhibitors. An Application in an Asthma Model.

Maud Bollenbach, Simona Nemska, Patrick Wagner, Guillaume Camelin, François Daubeuf, Adeline Obrecht, Pascal Villa, Didier Rognan, Frédéric Bihel, Jean-Jacques Bourguignon and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Maud BollenbachLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
Simona NemskaLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
Patrick WagnerLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.ORCID 0000-0002-8273-8329
Guillaume CamelinLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
François DaubeufLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
Adeline ObrechtInstitut du Médicament (IMS), F-67000 Strasbourg, France.
Pascal VillaInstitut du Médicament (IMS), F-67000 Strasbourg, France.ORCID 0000-0003-3466-4852
Didier RognanLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
Frédéric BihelLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
Jean-Jacques BourguignonLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
Martine SchmittLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.ORCID 0000-0002-8723-9502
Nelly FrossardLaboratoire d'Innovation Thérapeutique UMR 7200, CNRS, Faculté de Pharmacie, Université de Strasbourg, F-67400 Illkirch, France.
Centre National de la Recherche Scientifique · FR

Funding

Association Vaincre la Mucoviscidose PRTP13/10 2010, RF20140501176, RF2016051629, RF2016052094Laboratory of Excellence Medalis, Initiative of Excellence (IdEx), Strasbourg University, France NA
6 · The paper itself

Abstract

Mitogen- and Stress-Activated Kinase 1 (MSK1) is a nuclear kinase, taking part in the activation pathway of the pro-inflammatory transcription factor NF-kB and is demonstrating a therapeutic target potential in inflammatory diseases such as asthma, psoriasis and atherosclerosis. To date, few MSK1 inhibitors were reported. In order to identify new MSK1 inhibitors, a screening of a library of low molecular weight compounds was performed, and the results highlighted the 6-phenylpyridin-2-yl guanidine (compound

Indexed as

Drug DesignCells, CulturedGuanidinesHumansMolecular StructureProtein Kinase InhibitorsRibosomal Protein S6 Kinases, 90-kDaGuanidinesmitogen and stress-activated protein kinase 1Protein Kinase InhibitorsRibosomal Protein S6 Kinases, 90-kDaasthmainflammationkinase inhibitorsMSK1Pyridine-2-yl guanidine

Identifiers

PMID33450992
PMCPMC7828447
OpenAlexW3119388575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.